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Abstract: Mastectomy is a common surgical treatment used in the management of breast 
cancer but has associated physical and psychological consequences for the patient. Breast 
conservation surgery (BCS) is an alternative to mastectomy but is only possible when the 
tumour is of an appropriate size. Neo-adjuvant chemotherapy has been successfully used to 
downstage tumours and increase the number of patients eligible for BCS. However, the 
chemotherapies used in this approach are non-targeted and often result in significant side 
effects to the patient. In this manuscript, we evaluate the potential of ultrasound targeted 
microbubble destruction (UTMD) to deliver Rose Bengal-mediated sonodynamic therapy 
(SDT) in combination with paclitaxel (PTX) and doxorubicin (Dox) chemotherapy as a potential 
treatment for breast cancer. Efficacy of the combined treatment was determined in a three-
dimensional (3D) spheroid model of human breast cancer and in a murine model of the 
disease bearing subcutaneous MCF-7 tumours. The results demonstrated a significant 
reduction in both the cell viability of spheroids and tumour volume following treatment with the 
drug loaded microbubbles and ultrasound compared to targets treated with the drug loaded 
microbubbles alone or a Cremophor EL suspension of PTX and Dox. In addition, the weight 
of animals that received the microbubble treatment was unchanged throughout the study while 
a reduction of 12.1% was observed for animals treated with a Cremophor suspension of 
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PTX/Dox. These results suggest that UTMD-mediated chemo-sonodynamic therapy is an 
efficacious and well tolerated approach for the treatment of breast cancer.  
 
Keywords: Chemotherapy, sonodynamic therapy, microbubbles, ultrasound targeted 
microbubble destruction, breast cancer, MCF-7.  
 
1.0 Introduction: Breast cancer is the most prevalent form of cancer worldwide with 55,200 
new cases reported in the UK alone in 2015.1 Mastectomy is a common treatment for breast 
cancer with approximately 19,000 mastectomy surgeries performed in the UK each year.2 As 
the physical and psychological effects of this treatment can be considerable, there is a growing 
need for more effective non-surgical treatments to reduce the overall mastectomy rate. Neo-
adjuvant chemotherapy has been used to downstage tumours in advance of surgery and 
enable their removal by less invasive lumpectomy.3,4 This approach has proven effective in 
increasing the number of patients eligible for breast conserving surgery without posing a risk 
to the overall or progression-free survival rate.5 However, the chemotherapies used in these 
regimens are non-targeted to tumour tissue and cause significant off-target effects.6 
 Ultrasound targeted microbubble destruction (UTMD) has emerged as a promising 
strategy for the site-specific delivery of drug payloads to solid tumours.7 Microbubbles (MB) 
are lipid or polymer stabilised gas filled microspheres that have found clinical use as contrast 
agents in diagnostic ultrasound (US) applications. At low acoustic pressures, the MBs 
resonate in a symmetric manner and this feature helps improve the quality of the US image.8 
At higher acoustic pressures, inertial forces dominate resulting in microbubble collapse and 
ultimately destruction of the MB.9 When drug payloads are incorporated within the MB 
structure, they become deposited at the site of destruction.8  As US energy can be tightly 
focussed in three dimensions in human tissue, it is therefore possible to use UTMD to 
selectively deliver payloads to target sites with limited damage to surrounding tissue.9 
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We have previously demonstrated in pre-clinical experiments the utility of UTMD as an 
effective strategy for the delivery of chemotherapy and sonodynamic therapy (SDT) to 
pancreatic tumours.10 SDT is an emerging cancer treatment and involves the activation of an 
otherwise harmless sensitiser drug with low-intensity US to generate cytotoxic levels of 
reactive oxygen species (ROS).11-14 As oxygen is a key substrate for the generation of ROS 
in SDT, we have demonstrated that filling the core of MBs with oxygen gas enhances the ROS 
yield and SDT mediated cytotoxic effect observed.15 Our previous work has also shown that 
combining SDT with antimetabolite chemotherapy is more effective than either treatment 
alone at controlling the growth of pancreatic tumours.10, 16  Moreover, by using UTMD as a 
drug delivery strategy, it was possible to achieve targeted delivery to the tumours and 
significantly reduce  the overall amount of chemotherapy administered. 
 In this study, we adopted a similar approach using MBs to facilitate delivery of chemo-
sonodynamic therapy for the treatment of breast cancer. Doxorubicin (Dox) and paclitaxel 
(PTX), which are commonly used in the management of breast cancer, were selected as 
chemotherapies while Rose Bengal (RB) was used as the SDT sensitiser. PTX is a notoriously 
hydrophobic drug with a LogP of approximately3.5 17 and was incorporated within the 
hydrophobic acyl chain layer of the MB shell, while the hydrophilic Dox was modified to include 
a biotin anchor that enabled its attachment to the MB surface using the biotin-avidin 
interaction. As in our previous work, a biotin derivative of RB was also prepared to facilitate 
attachment to the MB surface.11 The resulting MBs were characterised in terms of size, 
concentration and drug loading while the efficacy of MB mediated chemo-sonodynamic 
therapy was determined in a three-dimensional (3D) spheroid model of human breast cancer 
and in a murine model of the disease bearing subcutaneous MCF-7 tumours.  
2.0 Materials & Methods. 
2.1 Reagents and Materials: 1,2-dibehenoyl-sn-glycero-3-phosphocholine (DBPC) and 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] 
(DSPE-PEG(2000)) and DSPE-PEG(2000)-biotin were purchased from Avanti Polar Lipids 
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(Alabaster, Alabama, USA). Avidin (Egg White) was purchased from Thermo Fisher Scientific 
(Waltham, Massachusetts, USA). Oxygen and nitrogen gas was purchased from BOC 
Industrial Gases (Guildford, UK)and perfluorobutane (PFB) was purchased from Apollo 
Scientific Ltd (Cheshire, UK). Phosphate Buffered Saline (PBS), streptomycin, Dulbecco’s 
Modified Eagle’s Medium (DMEM) and  Propidium Iodide (P.I.) were purchased from Thermo 
Fisher Scientific (Massachusetts, USA). Matrigel was purchased from Corning (New York, 
USA). Severe combined immunodeficient (SCID) (C.B-17/IcrHan®Hsd-Prkdcscid) mice were 
purchased from Charles River Laboratory (Massachusetts, USA).   Paclitaxel and biotin were 
purchased from XABC (Xi'an, China). Doxorubicin was purchased from LC Laboratories 
(Boston, MA, USA).  All other chemicals were purchased from Sigma Aldrich (Gillingham, UK) 
at the highest grade possible. MCF-7 cells were purchased from American Type Culture 
Collection (ATCC, Rockville, MD, USA). CellCarrier Ultra ULA-Coated 96-well Microplates 
were purchased from Perkin Elmer (Massachusetts, USA). Analytical HPLC analysis was 
undertaken using a Shimadzu HPLC (Shimadzu, Kyoto, Japan) fitted with an SPD-M20A 
photo-diode array detector and a Phenomenex C18 column (Phenomenex, California, USA) 
(250 × 4.6 mm, 5 μm). UV-Vis analysis was performed using a Varian-50 Bio UV-Visible 
spectrophotometer (Varian, California, USA). Optical microscope images were obtained using 
a Leica DM500 optical microscope (Leica, Wetzlar, Germany). MTT absorbance was analysed 
using a FLUOstar Omega microplate reader (BMG Labtech, Ortenberg, Germany). 
Fluorescence images were obtained using a NIKON Eclipse E400 Phase contrast microscope 
(Nikon, Tokyo, Japan) (540 nm band pass excitation and 590 nm long pass emission filters, 
respectively). NMR spectra were recorded on a Varian 500 MHz spectrometer (Varian, 
California, USA). ESI-MS characterisation was achieved using a LCQTM quadrupole ion-trap 
mass spectrometer (Finnigan MAT, California, USA) utilising electrospray ionisation (ESI).  
2.2  Synthesis of Biotin-Dox (5):  Biotin-N-hydroxysuccinimide ester (3) was prepared by the 
reaction of biotin (1) and N,N-Disuccinimidyl carbonate (2) following a literature procedure.18 
To an ice cold solution of 3, (0.14g, 0.41 mmol ) in DMF (10 ml) was added doxorubicin (4, 
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0.3g, 0.41mmol) under a nitrogen atmosphere. After stirring for 30 min, triethylamine (0.5 ml, 
2 mmol) was added to the reaction mixture and the contents stirred for 12 h at room 
temperature. The reaction was monitored by thin layer chromatography (TLC) (Merck Silica 
60, HF 254, 20: 80 methanol-dichloromethane v/v). After completion of the reaction, excess 
diethyl ether (100 ml) was added to the reaction mixture. The resultant red precipitate was 
filtered and washed three times with diethyl ether (50 ml X 3). The solid was then subjected to 
preparative thin layer chromatography (PTLC) purification (methanol-dichloromethane (20:80, 
v/v)) to obtain 0.25g (Yield = 78%) of 5. 1H NMR (DMSO-d6)δ :7.84 (d, J = 7.5 Hz, 2H, 
aromatic), 7.58 (d, J = 7.5 Hz, 1H, aromatic), 6.36 (s, 1H, NH), 6.29 (s, 1H, NH), 5.37 (brs, 1H, 
OH), 5.22 (brs, 1H, OH), 4.87 (s, 2H, -CH2-OH), 4.51 (brs, 2H, OH X 2), 4.36-4.33 (m, 1H, 
CH), 4.25-4.22 (m, 1H, CH), 4.16-4.13 (m, 1H, CH), 3.99 (s, 3H, OCH3), 3.60-3.58 (m, 1H, 
CH), 3.55 (brs, 2H, OH X2),  3.10-3.00 (m, 4H, CH2 X1, CH X 2), 2.88-2.54 (m, 3H, CH2 X 1, 
CH), 2.20-2.00 (m, 1H, CH), 1.63-1.50 (m, 4H, CH2 X 2), 1.42-1.22 (m, 11 H, CH3 X 1, CH2 X 
4). 13CNMR (DMSO-d6): 177.6, 176.9, 174.8, 166.4, 163.0, 161.2, 153.7, 152.7, 137.4, 132.4, 
120.4, 119.4, 99.5, 97.8, 80.15, 75.1, 72.7, 66.4, 61.4, 59.5, 55.7, 47.8, 33.8, 31.9, 28.9, 28.8, 
28.5, 28.4, 24.9, 19.8, 17.6, 17.1.  Negative mode electrospray mass spectrum: ESI-MS [M-
H]: calculated for C37H43I2N3O13S = 769 Da, found = 768 Da. 
2.3 Preparation of oxygen carrying microbubbles loaded with PTX in the shell and 
biotin-Dox or biotin-RB attached to the MB surface: Avidin-functionalised PTX-loaded MB 
were prepared by first dissolving 1,2-dibehenoyl-sn-glycero-3-phosphocholine (DBPC) 
(4.0mg, 4.44umol), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol) -2000] (DSPE-PEG(2000)) (1.35mg, 0.481umol) and 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[biotinyl(polyethylene glycol)-2000] 
(ammonium salt) (DSPE-PEG (2000)-biotin) (1.45mg, 0.481umol) in chloroform to achieve a 
molar ratio of 82:9:9. To this solution was added paclitaxel (7, 5mg, 5.86 µmol) dissolved in 
chloroform (100 µL). The solvent was removed under vacuum at room temperature yielding a 
translucent film. The film was then reconstituted in 2mL of a solution containing PBS, glycerol 
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and proplyene glycol (8:1:1 volume ratio) and heated in a water bath at 80oC for 30 min. The 
suspension was sonicated using a Microson ultrasonic cell disrupter at an amplitude of 22% 
for 1 min and then at an amplitude of 90% in a perflourobutane (PFB) atmosphere for 30 sec. 
The MBs were then cooled on ice for 10 min followed by centrifugation at 100 rcf for 3 min and 
the liquid laying below the surface of the MB cake (infranatant) was removed. The PTX-MB 
cake was then washed a further 2 times with PBS (pH 7.4 ± 0.1) before being mixed for 5 min 
on ice with an aqueous solution of avidin (10 mg/mL) using an orbital shaker (150 rpm). The 
PTX-MBs were then centrifuged (100 rcf) for 3 min, the infranatant removed and the MB cake 
washed with PBS solution (2 mL, pH 7.4 ± 0.1) which was again removed following 
centrifugation. The PTX-MB cake was again reconstituted in PBS solution (2 mL, pH 7.4 ± 
0.1), mixed for 5 min with an aqueous solution containing either biotin-Dox (5) or biotin-RB (6) 
(1mL, 5mg / mL) and centrifuged (100 rcf) for 3 min. Following removal of the infranatant, the 
MB cake was then washed with PBS (2 mL, pH = 7.4 ± 0.1), centrifuged and the MB cake 
isolated. This washing / centrifugation procedure was repeated twice further with the final PTX-
Dox MB / PTX-RB MB cake reconstituted in 2 mL of PBS. The final MB number was 
determined on a haemocytometer using an optical microscope. Size distribution analysis was 
carried out using imageJ image analysis software. MBs were sparged with oxygen gas for 2 
min immediately prior to use. Fluorescence imaging of PTX-RB MB and PTX-DOX MB were 
performed using a Nikon Eclipse E400 epi-fluorescence microscope equipped and the G-2A 
longpass emission filter set (λEX 510–560, 80% transmission with a 590 nm cut-on wavelength 
of the longpass emission). The drug loading on the surface of the MBs was determined using 
UV–Vis spectroscopy for 5 and 6 measuring the intensity at 480nm or 560nm respectively. 
Samples were prepared by firstly destructing (bursting) the MB using an ultrasound bath 
before removing a known volume and diluting with PBS. The drug loading  for 7 was 
determined using reverse phase HPLC, using a Phenomenex C18 column (250 × 4.6 mm, 5 
μm), a mobile phase consisting of acetonitrile: water (50:50 v/v), a flow rate of 1.5 mL/min−1 
using 227 nm as the detection wavelength. The loading  of PTX was calculated by the following 
equation: loading = amount of PTX loaded into the MB / total amount of lipid material x 100%. 
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2.4 Clonogenic assay to determine the cytotoxicity of Dox, PTX, SDT and combinations 
of each in MCF-7 cells: The human breast adenocarcinoma  cell line (MCF-7) was cultured 
in DMEM supplemented with 10% FBS, 100 µg/ml streptomycin and maintained in a 
humidified, 5% CO2 atmosphere at 37°C. MCF-7 cells were seeded (5 x103) into each well of  
a 96 well plate and 24 h later cells were treated with  PTX (1nM), Dox (10nM), RB (10nM) or 
combinations thereof for 3 h, followed by medium replacement.  Selected wells were treated 
with ultrasound for 30 s delivered using a Sonidel SP100 sonoporator using a frequency of 1 
MHz, an US power density of 3.0 W/cm2 and a duty cycle of 50% (pulse frequency = 100 Hz).  
After 18 h, cells were pooled from 2 wells and seeded in a 6 well plate containing 5 ml of 
complete media.  Plates were placed in an incubator for 7 days.  Medium was removed from 
wells and fixation/staining solution (1mL) [consisting of crystal violet (0.05% w/v), 
formaldehyde (2.7% v/v), PBS (10% v/v), methanol (1% v/v) and distilled water (86.3% v/v)] 
was added to each well at room temperature for 20 min. The solution was removed and wells 
were washed with water.  Digital photographs were taken using a Canon EOS100D DSLR and 
colony formation was analysed using Image J software. 
2.5 Preparation of 3D MCF-7 spheroids: Spheroids were generated by growing MCF-7 cells 
in 96 well Carrier Plates (ULA) from PerkinElmer. Cells were seeded (8 x103, 100µL) in 
selected wells. After 24 h, 100 µl of medium was added to each well and plates were incubated 
at 37°C in a humidified 5% CO2 atmosphere for a further 3 days to allow the cells to aggregate. 
Medium was replenished every 3 days by removing 100 µL of old media and replacing it with 
100 µL of fresh media. 
2.6 Chemo-sonodynamic therapy treatment of MCF-7 Spheroids using O2MB-PTX-Dox 
/ O2MB-PTX-RB ± ultrasound: Three days after seeding, spheroids were allocated to groups 
and treated according to the following conditions: untreated (drug-free medium), O2MB (no 
drugs), PTX/Dox only ([PTX] = 0.34 µM, [Dox] = 1 µM), and O2MB-PTX-Dox / O2MB-PTX-RB 
([Dox] = 1 µM, [RB] = 10 µM). Where required, individual wells were then placed in direct 
contact with the emitting surface of a Sonidel SP100 sonoporator with US gel used to mediate 
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contact. Each well was treated with US for 30 s using a frequency of 1 MHz, an US power 
density of 3.0 W/cm2 and a duty cycle of 50% (pulse frequency = 100 Hz).  Plates were  
incubated in a humidified 5% CO2 atmosphere at 37 °C for 3 h and then wells were washed 3 
times with PBS before fresh medium was added. 48 h after treatment, 5 spheroids per 
replicate from each condition were collected in an Eppendorf tube, washed with PBS and then 
incubated with trypsin/EDTA for 15 min at 37°C. The resultant cellular suspension was then 
incubated for 3 h with MTT [10 µl (5mg/mL) in 100 µl of medium). The absorbance was then 
measured at 570 nm using FLUOstar Omega microplate reader. Data were expressed as % 
cell viability by comparison with untreated controls. 
 In addition to MTT analysis, propidium iodide (P.I.) staining was also performed to 
determine cellular damage to the spheroid corona. Following treatment, spheroids were 
washed 4 times with PBS to remove excess medium and then incubated with a solution of P.I. 
in PBS (100 μg/ml). Spheroids were then incubated in the dark at RT for 40 min and then 
washed 3 times with PBS to remove excess P.I. Micrographic images were recorded using a 
NIKON Eclipse E400 Phase contrast microscope in bright field and fluorescence modes (540 
nm band pass excitation and 590 nm long pass emission filters). Image J software was used 
to quantify P.I. fluorescence and it was expressed as a % of P.I. fluorescence intensity/µm2, 
i.e. the P.I. fluorescence was normalized according to the area of the spheroid. 
2.7 Cytotoxicity of chemo-sonodynamic therapy in vivo using O2MB-PTX-Dox / O2MB-
PTX-RB ± ultrasound: All animals employed in this study were treated humanely and in 
accordance with licenced procedures under the UK Animals (Scientific Procedures) Act 1986. 
MCF-7 cells (5 x106) in 100 μL Matrigel were sub-cutaneously implanted into the rear dorsum 
of 8-week old female SCID (C.B-17/IcrHan®Hsd-Prkdcscid) mice. Palpable tumours appeared 
approximately 1-2 weeks after cell implantation. Once tumours became palpable, dimensions 
were measured using Vernier callipers. Tumour volume was calculated using the equation:  
tumour volume = (length x width2)/2.  Once tumours reached approximately 65 mm3 animals 
were separated into the following groups:  Group 1 remained untreated, groups 2 and 3 
received an intravenous (IV) injection (50 µL) of a mixed suspension of O2MB-PTX-RB and 
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O2MB-PTX-Dox (6.18x107 MB, [PTX] = 1.13 ± 0.16 mg / kg, [RB] = 2.63 ± 0.35 mg / kg, [Dox] 
= 0.97 ± 0.15 mg / kg with (group 2) or without (group 3) ultrasound exposure. Group 4 
received an I.V injection (100 μL) of a Cremophor suspension containing PTX (4.7 mg / kg) 
and Dox (2.5 mg / kg).  Ultrasound was administered directly to the tumour site using a Sonidel 
SP100 sonoporator (3.5 Wcm-2, 1 MHz, 30% duty cycle, and PRF = 100 Hz; PNP = 0.48 MPa; 
M.I. = 0.48) during, and 30 min after IV administration (for a total of 7.0 min) using ultrasound 
gel to mediate contact. Animals were treated on days 0, 7 and 21 and both the tumour volume 
and body weight measurements recorded at the indicated times.  
2.8 Statistical Analysis: Error was reported as ± standard error of the mean. Statistical 
analysis was undertaken using a GraphPad Prism software package (IBM, UK). Group-wise 
comparisons were made using one-sided parallel group t-tests with a p-value less than 0.05 
deemed significant.   
3.0 Results and Discussion:  In advance of preparing and testing the drug loaded O2MBs, 
we were first interested in determining the effectiveness of combining PTX, Dox and SDT on 
the treatment of MCF-7 cells. In this study, the concentration of each individual drug used was 
intentionally sub-lethal (i.e. drug concentrations that had no impact on cell viability), so that 
any benefit obtained by the combination treatment could easily be identified. In addition, as 
the action of US can influence the cellular uptake of drugs due to sonoporation, cells treated 
with Dox or PTX were also exposed to US, to control for any potential effects as a result of US 
exposure during SDT treatment.19 Following treatment, cell viability was then determined using 
a clonogenic assay. The results are shown in Figure 1 and reveal no reduction in colony 
number for cells treated with a combination of PTX, Dox and RB in the absence of US 
compared to untreated cells. Treatment of cells with PTX + US, RB + US (i.e. SDT) or Dox + 
US reduced colony number by 7.3, 18.8 and 29.3% respectively compared to untreated cells, 
while cells treated with combined PTX, Dox and RB + US reduced the colony number by 
44.0%. The lack of efficacy for the combined drug cocktail in the absence of US was not 
surprising as sub-lethal doses of the drugs were used. However, the significant improvement 
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in efficacy following exposure to US may result from a sonoporative effect that improves the 
uptake of these drugs. The fact that the greatest reduction in colony number was observed for 
the combined PTX, Dox and SDT treatment group indicates that these three treatments 
complement each other and improve the overall cytotoxic effect observed.  
Encouraged by these results, the next step was to incorporate the PTX, Dox and RB 
into the MB delivery vehicle. Two MB formulations were prepared (Figure 2): the first 
comprised PTX loaded in the hydrophobic acyl layer of the MB shell while biotin-Dox was 
attached to the MB surface using the biotin-avidin linkage (O2MB-PTX-Dox); the second 
formulation also had PTX loaded in the MB shell but with biotin-RB attached to the MB surface 
(O2MB-PTX-RB).   
To attach RB and Dox to the O2MB surface it was necessary to modify each compound 
to contain biotin functionality. We have described the preparation of biotin-RB before in a 
previous communication.11 However, the preparation of biotin-Dox has not yet been reported 
and was synthesised according to Scheme 1. Briefly, biotin (1) was first reacted with N,N′-
disuccinimidyl carbonate (2) to form the corresponding NHS activated ester (3). Dox (4) was 
then attached to 3 via an amidation reaction to form the target compound biotin-Dox (5) which 
was isolated following preparative TLC purification and its structure confirmed using NMR and 
mass spectroscopy.  
Following their preparation, O2MB-PTX-Dox and O2MB-PTX-RB were characterised 
using optical and fluorescence microscopy (Figure 3) while the drug loading was determined 
using UV-Vis spectroscopy (for RB and Dox) and HPLC (for PTX). Analysis of optical 
microscope images confirmed the presence of spherical O2MB-PTX-Dox and O2MB-PTX-RB 
microbubbles with mean particle diameters of 2.82 ± 0.05 and 2.61 ± 0.02 µm respectively 
and mean microbubble concentrations of 1.2 x 109 and 1.35 x 109 MB / mL respectively. Both 
O2MB-PTX-Dox and O2MB-PTX-RB also exhibited bright red fluorescent shells when 
analysed using fluorescent microscopy consistent with the successful attachment of the 
inherently fluorescent Dox and RB respectively (Figure 3). The mean loading of PTX, Dox and 
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RB onto the MBs was determined to be 51.8 ± 8.3 μg / 108 MBs, 41.3 ± 2.6 µg / 108 MBs and 
140.0 ± 23.4 µg /108 MBs respectively. This reflects a loading  for PTX of 23.5 ± 1.8 % which 
compares favourably with previous studies where PTX was loaded hydrophobically within the 
MB shell.20, 21 One potential complication of loading PTX in the MB shell is that it could 
compromise the subsequent loading of biotinylated payloads to the MB surface. To determine 
if this was the case, batches of MBs with or without PTX in the shell were prepared and the 
ability to attach biotin-RB to the surface determined. The results are shown in Figure 4 and 
reveal no significant change in the loading of biotin-RB in the absence or presence of PTX. 
Indeed, the loadings achieved for both PTX and DOX using the approach adopted in this study 
suggest it would be possible to deliver clinically relevant doses of both agents PTX (175mg/m2) 
and DOX (25mg/m2) as a part of the MB platform whilst remaining within the tolerated MB 
dose determined in primates (i.e. 3.31 x 1011 MBs to deliver 175mg/m2 PTX and 0.609 x 1011 
MBs to deliver 25mg/m2 DOX).22 Off course, targeting delivery using UTMD means it should 
be possible to use much lower concentrations of these toxic chemotherapy drugs while 
maintaining an effective therapeutic outcome.  
Having successfully prepared and characterised the O2MB-PTX-Dox and O2MB-PTX-
RB conjugates, the next step was to determine their efficacy in a 3D spheroid model of breast 
cancer. This model was chosen over the more conventional two-dimensional (2D) cellular 
monolayer as the heterogeneous architecture of a 3D spheroid more closely resembles that 
of in vivo solid tumours and thus is a valuable tool in the screening of new drugs and drug 
delivery systems.23 Spheroids were treated with O2MB only (i.e. no drugs attached), PTX / Dox 
only (i.e. not MB bound) and the O2MB-PTX-Dox / O2MB-PTX-RB conjugates in the presence 
and absence of US. Untreated spheroids and spheroids treated with US only were also 
included for comparative purposes. Following treatment, the extent of cell viability was 
determined using an MTT assay and also by staining the spheroids with propidium iodide (P.I.) 
following treatment.  
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Results from the MTT assay are shown in Figure 5 and reveal a moderate reduction 
in the viability of cells following exposure to US alone (28.03%, p<0.05), which was similar to 
the reduction observed for the O2MB + US treatment (29.40 %). Treatment of PTX / Dox alone 
reduced viability by 21.98% (p<0.05) relative to untreated spheroids, which was broadly 
unchanged in the presence of ultrasound (23.67%). However, when spheroids were treated 
with the O2MB-PTX-Dox / O2MB-PTX-RB conjugates and US, the cell viability decreased by 
72.6% which was significantly greater than treatment with the O2MB-PTX-Dox / O2MB-PTX-
RB conjugates in the absence of US (8.2%) or the other groups. This improved cytotoxicity is 
most likely due to both SDT and the ability of O2MB induced cavitation to enhance dispersion 
of the drugs within the spheroid matrix.24 Indeed, MB cavitation is known to create associated 
microstreaming and microjetting events that have been attributed to improved tumour uptake 
and efficacy of chemotherapy drugs in several pre-clinical and clinical studies.25-27 
Results from the P.I. staining experiments revealed a slightly different trend from those 
obtained using the MTT assay. P.I. is a DNA selective permeable dye that passes freely 
through compromised plasma membranes of dead cells and does not permeate the 
membrane of living cells.28 In contrast to the MTT assay experiments, where a single cell 
suspension of cells derived from spheroids was analysed post-treatment, intact spheroids 
were examined following treatment using P.I. staining. The brightfield and fluorescent images 
from each treatment group are shown in Figure 6a with the fluorescence intensity quantified 
and plotted in Figure 6b. Bright red P.I. fluorescence was observed for spheroids treated with 
the O2MB-PTX-Dox/O2MB-PTX-RB + US group which was significantly more intense than any 
of the other groups. It was also noticed that the mean volume of spheroids treated with O2MB-
PTX-Dox/O2MB-PTX-RB + US was significantly smaller than in any of the other groups 
including those spheroids treated with O2MB-PTX-Dox / O2MB-PTX-RB in the absence of US. 
Combined, the intense P.I. fluorescence and size reduction observed for spheroids treated 
with O2MB mediated chemo-sonodynamic therapy, in addition to the reduced cell viability 
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observed from the MTT assay experiments, highlight the effectiveness of this treatment in this 
particular model of breast cancer. 
While encouraged by the results obtained from the 3D spheroid experiments, the full 
utility of O2MBs as a delivery vehicle can only be determined in vivo. To this end, 
subcutaneous MCF-7 tumours were established in recipient mice and a mixed suspension of 
the O2MB-PTX-Dox / O2MB-PTX-RB formulations was administered to animals by IV injection. 
During injection, US was positioned at the tumour to disrupt the O2MB, release the payloads 
and activate SDT, where appropriate. To evaluate the effectiveness of the O2MB delivered 
treatments, a group of animals were also treated with a combination of free PTX / Dox (i.e. not 
O2MB attached). The tumour growth delay plot is shown in Figure 7 and reveals a significant 
reduction in tumour volume for animals treated with O2MB-PTX-Dox / O2MB-PTX-RB + US, 
with tumours still 11.44% smaller than the pre-treatment size 25 days after the initial treatment. 
In contrast, tumours in animals treated with the same O2MB-PTX-Dox / O2MB-PTX-RB 
formulation in the absence of ultrasound increased in volume by 40.47 % over the same time 
period. Indeed, the effect of O2MB-PTX-Dox / O2MB-PTX-RB + US was also significantly better 
than that observed following treatment using the free PTX / Dox combination which increased 
in volume by 18.90% at day 25, despite receiving a 16.8% and 98.4% increased dose of PTX 
and Dox respectively. Combined, these results corroborate the in vitro efficacy results and 
highlight the effectiveness of O2MB delivered chemo-sonodynamic therapy as a targeted 
treatment for breast cancer. In addition to the improved efficacy offered by this approach, the 
treatment was also well tolerated with the body weight of animals in the O2MB treated groups 
mapping closely to that of untreated animals. In contrast, there was a 12.1% drop in body-
weight for animals treated with free PTX / Dox over the course of the experiment. This 
reduction in body weight most likely results from toxicity exhibited by the free drugs or the 
Cremophor EL vehicle required to deliver PTX. Cremophor EL is known to produce 
undesirable side-effects and while poorly tolerated,29-31 is necessary to enable the dispersion 
of hydrophobic PTX in aqueous solution. Therefore, the ability to avoid the use of such a toxic 
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vehicle by incorporating PTX within the O2MB shell is an added advantage of the microbubble-
based drug delivery system. 
In conclusion, the use of O2MBs offer an attractive vehicle for the delivery of a chemo-
sonodynamic therapy to solid breast tumours. The improved efficacy of O2MB delivered 
chemo-sonodynamic therapy, when compared to standard PTX / Dox treatment was 
demonstrated in both in vitro and in vivo models of the disease. In particular, the reduction in 
tumour volume, observed following treatment with O2MB-delivered chemo-sonodynamic 
therapy, offers significant potential as a neo-adjuvant therapy to downstage tumours in 
advance of surgery, or, as a treatment for locally recurrent chest wall disease. An added 
advantage of this approach is that each component part of the treatment (i.e. the MBs, PTX, 
Dox, RB and US) has been safely used in humans previously thus providing the opportunity 
for rapid clinical translation.  
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Figure 1. Plot showing % of surviving MCF-7 cells for each of the treatment groups. Cells 
were treated with PTX +US (1nM), Dox +US (10nM), RB +US (10nM) and PTX + Dox + RB 
+US ([PTX] = 1nM, [Dox] = 10nM, [RB] = 10nM). After treatment, cells were incubated for 8 
days followed by fixation and staining.  Crystal violet staining of representative images are 














































Scheme 1. Synthetic scheme for the synthesis of biotin-Dox (5). Also shown are the structures 












Figure 3. Representative bright field (left panel) and fluorescence (middle panel) micrographs 



























Figure 4. Plot of Rose Bengal loading (normalized to 108 MBs) in the absence (0 mg) and 
presence (5mg) of paclitaxel incorporated within the lipid layer during MB formulation (final 






































Figure 5. Plot of cell viability for 3D MCF-7 spheroids following exposure to (i) no treatment 
(ii) O2MB only (no drugs), (iii) PTX/Dox only (i.e. no O2MBs) ([PTX] = 0.34 µM, [Dox] = 1 µM)  
or (iv) O2MB-PTX-Dox/O2MB-PTX-RB ([Dox] = 1 µM, [RB] = 10 µM)  in the presence or 
absence of US.: *p < 0.05, ***p < 0.001 for treatment groups compared to untreated group. 
&&p < 0.01 for O2MB-PTX-Dox/O2MB-PTX-RB + US v PTX/Dox + US.  $$$p < 0.001 for O2MB-
PTX-Dox/O2MB-PTX-RB + US v O2MB-PTX-Dox/O2MB-PTX-RB – US. Error bars represent ± 












Figure 6. (a) Optical (left panel) and fluorescence (right panel) micrographs of MCF-7 
spheroids exposed to: (i) no treatment, (ii) US only (iii) MB only, (iv) O2MB + US (v) PTX/Dox 
only ([PTX] = 0.34 µM, [Dox] = 1 µM), (vi) PTX / Dox + US (vii) O2MB-PTX-Dox / O2MB-PTX-
RB ([Dox] = 1 µM, [RB] = 10 µM) and (viii) O2MB-PTX-Dox / O2MB-PTX-RB + US. Spheroids 
were stained with P.I. following treatment. (b) plot of P.I. intensity per µM2 for each of the 
groups shown in (a) (normalized to 100% by comparison with O2MB-PTX-Dox / O2MB-PTX-
RB + US group).  *p < 0.05, **p < 0.01, ***p < 0.001 significance for treatment groups relative 
to untreated group. $$p < 0.01 significance for O2MB-PTX-Dox/O2MB-PTX-RB + US v O2MB-
PTX-Dox/O2MB-PTX-RB PTX/Dox + US. &&&p < 0.001 significance for O2MB-PTX-Dox/O2MB-





















Figure 7. (a) Tumour growth delay plot for mice bearing MCF-7 xenograft tumours. Control 
animals received no treatment.   Groups were treated with a mixed suspension (50 µL) of 
O2MB-PTX-RB and O2MB-PTX-Dox (6.18x107 MB, [PTX] = 1.13 ± 0.16 mg/kg, [RB] = 2.63 ± 
0.35 mg/kg, [Dox] = 0.97 ± 0.15 mg/kg) delivered by IV in the presence and absence of  US.. 
A group was also treated with Cremophor EL suspension containing free PTX and Dox ([PTX] 
= 4.7 mg / kg, [Dox] = 2.5 mg / kg) (b) Plot of animal weights recorded over the course of the 
experiment for each group.    For graphs (a) and (b) **p < 0.01, ***p < 0.001. Error bars 
represent ± SEM where n = 5. 
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